To evaluate the cost-effectiveness of recombinant human TNK tissue-type plasminogen activator(TNK) versus alteplase in adult patients with acute ischemic stroke from the perspective of Chinese health system.
Based on individual patient data from the phase Ⅲ clinical trial TRACE-2(NCT04797013) of TNK in China, a decision tree and Markov hybrid model was constructed to simulate both a 1-year short-term and a lifetime horizon. The incremental cost-effectiveness ratio(ICER) of TNK versus alteplase was calculated, and sensitivity analysis were performed to test the robustness of the results.
Compared with alteplase, TNK provided an incremental gain of 0.016 quality-adjusted life years(QALYs) and saved 65.29 yuan over a 1-year horizon, and provided 0.118 QALYs gained and saved 2 306.68 yuan over the lifetime horizon. TNK was dominant over alteplase in both time horizons.
From the perspective of the Chinese health system, TNK is cost-effective compared with alteplase for adult patients with acute ischemic stroke in China.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |